Innate Pharma And Sanofi's Blood Cancer Treatment SAR443579/IPH6101 Shows Over 10 Months Of Durable Complete Remission In Phase 1/2 Study, Results Discussed At EHA Congress
Innate Pharma And Sanofi's Blood Cancer Treatment SAR443579/IPH6101 Shows Over 10 Months Of Durable Complete Remission In Phase 1/2 Study, Results Discussed At EHA Congress
innate pharma和赛诺菲的血液癌症治疗SAR443579/IPH6101在1/2期研究中表现超过10个月的持久完全缓解，结果在EHA大会上讨论。
- SAR443579/IPH6101, ANKET platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS
- SAR443579/IPH6101 continues to show clinical benefit and durable responses along with a favorable safety profile in patients with R/R AML, with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg, with durable CR (>10 months) observed in 3 patient
- "We are pleased to see that SAR'579 continues to show promising and durable clinical efficacy along with a favorable safety profile. The ongoing Phase 1/2 study has recently progressed to the Phase 2 stage, marking a significant milestone in its development. We look forward to the continued progress of this multi-specific NK Cell Engager which holds great potential to benefit patients suffering from various blood cancers," says Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma.
- SAR443579/IPH6101，ANKET平台的领先资产，是首个基于NKp46/CD16的NK细胞结合剂，其靶向CD123，由Innate Pharma和赛诺菲共同研发，由赛诺菲在R / R AML，B-ALL和HR-MDS中进行开发。
- SAR443579/IPH6101在R/R AML患者中继续显示出临床效益和持久疗效，同时具有良好的安全性。在1mg / kg下取得5个完全缓解（4 CR / 1 CRi），在3个患者中观察到持久性的CR（> 10个月）。
- "我们很高兴看到SAR'579持续显示出有前途的和持久的临床效果，同时具有良好的安全性。正在进行的1/2期研究最近进展到2期阶段，在其发展中达成了重要里程碑。我们期待这种多重特异性NK细胞结合剂的进一步进展，该结合剂具有使患者受益于各种血液癌症的巨大潜力。Innate Pharma的首席医学官Sonia Quaratino博士表示：“这种多重特异性NK细胞结合剂具有巨大的潜力，可使患者受益于各种血液癌症。我们期待着其持续的进展。”,"说道Innate Pharma的首席医疗官Sonia Quaratino博士。